AOA Dx

AOA Dx focuses on early cancer detection. Their unique GlycoLocate platform uses AI to detect gangliosides that may be used as tumor biomarkers to enable earlier detection and effective monitoring. Gangliosides are molecules found within the cell membrane that are responsible for cell signaling and communication. When secreted by cancer cells, gangliosides can regulate tumor growth and impact anti-tumor immunity. AKRIVIS GD is the first test developed by AOA Dx through their GlycoLocate platform that can measure tumor marker gangliosides for early detection of ovarian cancer via liquid biopsy. AKRIVIS GD would be the first available method to enable early detection of ovarian cancer. AOA Dx aims to use their GlycoLocate platform to identify biomarkers for early detection and monitoring of other life-threatening cancers. Identifying tumor glycolipid biomarkers can also provide targets for precision immunotherapies.